Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 88Neoplasms 11Neoplasm Metastasis 10Glioma 8Ovarian Neoplasms 6Melanoma 6Glioblastoma 6Squamous Cell Carcinoma of Head and Neck 5Liposarcoma 5Carcinoma, Non-Small-Cell Lung 5Sarcoma 4Recurrence 4Medulloblastoma 4Endometrial Neoplasms 4Diffuse Intrinsic Pontine Glioma 4Colorectal Neoplasms 4Brain Neoplasms 4Neuroblastoma 3Neoplasms by Site 3Lymphoma 3Hereditary Sensory and Autonomic Neuropathies 3Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Diseases 3Astrocytoma 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Multiple Endocrine Neoplasia Type 1 2

Interventions

Cyclophosphamide 31Trastuzumab 30Paclitaxel 28Docetaxel 22Taxes 18Doxorubicin 18Lapatinib 15Radiotherapy 14Capecitabine 14Bevacizumab 13Tamoxifen 12Carboplatin 11Filgrastim 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Chemotherapy, Adjuvant 8exemestane 7Vorinostat 7Letrozole 7Immunohistochemistry 7Gemcitabine 7Anastrozole 7Albumin-Bound Paclitaxel 7pegfilgrastim 6Neoadjuvant Therapy 6Magnetic Resonance Spectroscopy 6Immunoenzyme Techniques 6Goserelin 6Flow Cytometry 6Everolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms, Male × ribociclib × Clear all
NCT05827081 2026-06-03

Adjuvant WIDER

Novartis

Phase 3 Recruiting
1,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02586675 2022-01-21

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
7 enrolled 8 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡